Symbiotec Pharmalab IPO Lists at ₹988 After 75.06x Demand
Key highlights
- Symbiotec listed at ₹988 per share on September 1, 2026, matching its final issue price.
- The ₹1,757 crore IPO was subscribed 75.06 times during August 24 to August 27, 2026.
- The offer included a ₹150 crore fresh issue and a ₹1,607 crore offer for sale.
- Symbiotec reported ₹872.26 crore revenue and ₹109.90 crore profit in 2026.
powered by IRIS

Symbiotec Pharmalab Limited listed at ₹988 per share on September 1, 2026, matching its ₹988 issue price after its ₹1,757 crore initial public offering was subscribed 75.06 times. The book-built offer had opened on August 24 and closed on August 27, with a ₹150 crore fresh issue and a ₹1,607 crore offer for sale.
How did Symbiotec list on the stock exchanges?
Symbiotec listed on both BSE and NSE at ₹988 per share, in line with the upper end of its ₹938 to ₹988 price band. The listing on September 1 followed finalisation of allotment on August 28 and refund or demat-credit activity scheduled for August 31.
Listing at the issue price means the stock did not record a premium or discount at debut based on the available information. The offer had generated substantial subscription demand during its August 24 to August 27 bidding window, with the reported subscription multiple standing at 75.06 times. Social-media discussion before the issue had focused on grey-market sentiment, but the available listing data show the actual opening was at the offer price.
What were the key terms of Symbiotec's ₹1,757 crore IPO?
Symbiotec's ₹1,757 crore IPO combined a ₹150 crore fresh issue with a ₹1,607 crore offer for sale by existing shareholders. The company offered 17,786,442 equity shares of face value ₹2 each at the final offer price of ₹988 per share.
The offer for sale included shares from Satwani Holdings LLP, Rosewood Investments and India Business Excellence Fund - III. Since the larger part of the transaction was an offer for sale, most of the stated IPO proceeds were linked to selling shareholders rather than the company’s fresh capital raise. The fresh issue component was fixed at ₹150 crore.
What was the retail investment requirement for Symbiotec?
Symbiotec required a minimum application of 15 shares, amounting to ₹14,820 at the upper price band of ₹988 per share. The offer reserved 35% for retail investors, 50% for qualified institutional buyers and 15% for high-net-worth investors.
The lot size and upper-band calculation are important because some circulating IPO details reported different minimum-investment figures. Based on the final price of ₹988 and a 15-share lot, ₹14,820 is the stated retail minimum. Investors received allotment information after the August 28 finalisation date, ahead of the September 1 listing.
Got a follow-up? Ask IRIS
What do Symbiotec's reported financial figures show?
Symbiotec reported revenue of ₹872.26 crore in 2026 and profit of ₹109.90 crore, compared with revenue of ₹755.98 crore and profit of ₹96.79 crore in 2025. The reported figures show an increase in both revenue and profit between the two periods.
Revenue increased by ₹116.28 crore, while reported profit rose by ₹13.11 crore. The company is described in the available material as an Indore-based pharmaceutical and biotechnology company with specialised API manufacturing, regulatory approvals and biotechnology capabilities. Discussion around the offer also referenced the contract development and manufacturing organisation market, which was projected in the supplied context to grow at an 8.2% CAGR.
Who managed the Symbiotec public issue?
Symbiotec appointed JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited as book-running lead managers. MUFG Intime India Private Limited was the registrar to the offer.
The anchor investor bid period was held on August 21, before the public subscription window began on August 24. The issue formed part of a busy late-August IPO calendar, with reports noting that 10 companies were seeking to raise more than ₹3,300 crore during that week. Symbiotec was described as the largest issue among those offerings.
Conclusion
Symbiotec completed a ₹1,757 crore public issue with strong reported demand of 75.06 times, but its shares began trading at ₹988, the same as the final offer price. The transaction paired a relatively smaller ₹150 crore fresh issue with a ₹1,607 crore offer for sale, while the company’s reported revenue and profit were higher in 2026 than in 2025.
Investors can watch the stock’s trading after the September 1 debut and assess how the reported growth in revenue and profit develops. Other relevant factors disclosed around the issue include the company’s pharmaceutical and biotechnology manufacturing positioning and the stated 8.2% CDMO market growth expectation.


